InevitableI've mentioned previously that TH a should announce a voluntary share consolidation. No institutional shareholder will want to be invested in a penny stock. At this point,
it becomes a purely cosmetic issue, if not internal rules for buying a stock. If I were to look at TH as an investment right now, I would try to figure out how many shares are held by institutions. That number will be out for a sale. Expect further price weakness.
A quick comment on those who crucified TH for doing an issue at $3.50 and celebrated their convertible deb when the stock was trading at $13: you issue STOCK, not debt, when your stock is expensive. That is how you minimize dilution. A biotech always needs to issue new shares by definition. They need to raise capital to fund their R$D. TH used to have 25m shares outstanding 20 years ago. Despite increasing this number to 75 million shares before the last runup in the share price, the stock went from 0.25$ to over 10$. So do not look at number of shares, follow the market cap.
There is a low probability that TH will comply with the minimum 1$ condition by next July. I don't see any positive surprises being announced in the next 6 months. If you want to make money with TH, you have to wait until it becomes ridiculously cheap, which it is not quite yet at this time. And wait until they issue new shares because that is also an inevitability. TH needs to find buyers which they need but who won't make any favours.